Please wait a minute...
European Journal of Gynaecological Oncology  2020, Vol. 41 Issue (4): 504-507    DOI: 10.31083/j.ejgo.2020.04.5192
Systematic Review Previous articles | Next articles
A systematic review and meta-analysis on the effects of metformin on survival outcomes and risk in women with cervical cancer
Yi-fan Luo1, 2, Li-xiang Ren3, Ming-yan Jiang1, Yang Chu1, 2, *()
1Department of Pharmacy, the First Affiliated Hospital of China Medical University, Shenyang 110001, P. R. China
2School of Pharmacy, China Medical University, Shenyang 110001, P. R. China
3Safety Evaluation Center, Shenyang Research Institute of Chemical Industry, Shenyang 110021, P. R. China
Download:  PDF(277KB)  ( 331 ) Full text   ( 14 )
Export:  BibTeX | EndNote (RIS)      
Abstract  
Objective: A systematic review and meta-analysis was conducted to quantitatively assess the effects of metformin on both the treatment and risk of cervical cancer in women. Materials and Methods: A search was conducted in a number of databases including CNKI, VIP, Wanfang Digital Journal Full-text Database, PubMed, Cochrane, and Web of Science. In accordance with inclusion and exclusion criteria screening in the literature, Newcastle-Ottawa scale and RevMan 5.3 software were employed to perform the meta-analysis. Results: A total of five studies taken from four articles involving 149,742 participants were finally included in meta-analysis, two random clinical trials (RCTs) and three retrospective cohort studies. Evaluation of metformin usage in two of the studies did not show significant association with five-year overall survival (OS) of patients receiving adjuvant whole-pelvic radiation therapy (WPRT) as a primary therapy compared to those . not using metformin (RR = 1.08, 95% CI 1.00-1.18, p = 0.06). In the three other studies metformin use was associated with a significant reduction in cervical cancer risk in diabetes mellitus patients (RR = 0.60, 95% CI 0.44-0.82, p = 0.001). Conclusion: Merformin use is associated with a reduction in cervical cancer risk in patients with diabetes mellitus, but is not associated with five-year OS of patients receiving WPRT. Further studies are required to confirm survival outcomes for use of metformin in cervical cancer.
Key words:  Cervical cancer      Meta-analysis      Metformin      Outcomes      Systematic review     
Submitted:  22 February 2018      Accepted:  03 June 2019      Published:  15 August 2020     
*Corresponding Author(s):  YANG CHU     E-mail:  15002422786@163.com

Cite this article: 

Yi-fan Luo, Li-xiang Ren, Ming-yan Jiang, Yang Chu. A systematic review and meta-analysis on the effects of metformin on survival outcomes and risk in women with cervical cancer. European Journal of Gynaecological Oncology, 2020, 41(4): 504-507.

URL: 

https://ejgo.imrpress.com/EN/10.31083/j.ejgo.2020.04.5192     OR     https://ejgo.imrpress.com/EN/Y2020/V41/I4/504

[1] Liman Yang, Jing Jin, Juhong Liu. Correlation of MMP2-C1306T (rs243865) and MMP7-181A/G (rs11568818) with cervical cancer: a meta-analysis[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 508-512.
[2] Panteleimon Mnimatidis, Abraham Pouliakis, George Valasoulis, George Michail, Aris Spathis, Christine Cottaridi, Niki Margari, Maria Kyrgiou, Maria Nasioutziki, Alexandros Daponte, Konstantinos Dinas, Evangelos Paraskevaidis, Ioannis Panayiotides, Dimitrios-Dionysios Koutsouris. Multicentric assessment of cervical HPV infection co-factors in a large cohort of Greek women[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 545-555.
[3] Krittiya Somaketarin, Charuwan Tantipalakorn, Kittipat Charoenkwan, Prapaporn Suprasert, Jatupol Srisomboon. Survival outcomes of sex cord-stromal tumors of the ovary[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 563-568.
[4] Fengmei Wang , Huachun Luo , Huihua Cheng, Huijuan Huang , Zhichao Fu. Is 3D printing-gided three-dimensional brachytherapy suitable for cervical cancer: from one single research institute?[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 591-597.
[5] Hiroshi Yoshida, Megumi Yamamoto, Hiroyuki Shigeta. Successful treatment of uterine cervical carcinoma with extensive vaginal lesions using laparoscopic surgery: A case report[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 629-633.
[6] Hikari Unno, Seiji Mabuchi, Isao Arai, Tomoko Wakasa, Seiichi Yamamasu. Development of lymphangiosarcoma after pelvic radiation therapy for uterine cervical cancer: A case report and literature review[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 326-331.
[7] B.-H. Zhang, L. Li, J. Ji, J. Guo, X.-L. Zhou, H. Xu, F. Cao, X.-H. Tong. Prognostic value of Foxp3+ regulatory T cells in endometrial cancer: a meta-analysis[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 339-342.
[8] L. Xu, H. Cai, N. Zhu, Bo Zheng. Interleukin-22 derived from cervical cancer-associated fibroblasts accelerates senescence of normal fibroblasts and promotes expression of tumorigenesis-related factors in HeLa cells[J]. European Journal of Gynaecological Oncology, 2020, 41(2): 192-199.
[9] Hong Yan, Chunhua Zhang, Tingting Liu, Jianzhong Liu. Mifepristone regulates the multidrug resistance via miR-758/MEPE of Hela cell lines[J]. European Journal of Gynaecological Oncology, 2020, 41(2): 214-220.
[10] K. Plagens–Rotman, M. Piskorz–Szymendera, B. PIĘTA. Lifestyle with particular emphasis on physical activity and genital carcinomas in women[J]. European Journal of Gynaecological Oncology, 2020, 41(2): 233-239.
[11] B. Bárány, R. Póka. Nutritional assessment among patients with cervical cancer and controls[J]. European Journal of Gynaecological Oncology, 2020, 41(1): 23-29.
[12] D. Kim, Y. Ki, W. Kim, D. Park, D. Suh, K. Kim, J. Lee, H. Jeon, J. Nam. Positive pelvic lymph node on [18F]-FDG PET is a prognostic factor in early-stage high-risk cervical cancer treated by radical hysterectomy and adjuvant chemoradiotherapy[J]. European Journal of Gynaecological Oncology, 2020, 41(1): 42-47.
[13] H. Imafuku, Y. Ebina, K. Suzuki, S. Wakahashi, Y. Miyahara, K. Yoshida, H. Yamada. Definitive radiotherapy in elderly patients and patients with locally advanced cervical cancer with complications[J]. European Journal of Gynaecological Oncology, 2020, 41(1): 60-64.
[14] Y. Murata, Y. Miyahara, K. Suzuki, S. Wakahashi, T. Sudo, S. Nagao, S. Yamaguchi, Y. Ebina, H. Yamada. Leukocytosis and thrombocytosis as prognostic factors for women with uterine cervical cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(1): 93-97.
[15] N. Habib, T. Dennis, G. Centini, L. Bresson, F. Narducci, E. Leblanc. Glassy cell carcinoma: is surgical treatment with preservation of the uterus a therapeutic option?[J]. European Journal of Gynaecological Oncology, 2020, 41(1): 121-125.
No Suggested Reading articles found!